3-D Matrix, Ltd.
DMTRF
Other OTC2.25
USD
- -
- -
ISIN
JP3410730000
Return %
Stock
S&P500
1Y
226.09
26.53
3Y
92.31
76.60
5Y
-6.25
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Keiji Nagano
- Full Time Employees
- 106
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- Kojimachi HF Building Tokyo Japan 102-0083
- IPO Date
- Jun 19, 2013
- Website
- 3d-matrix.co.jp
- Similar Companies
- Business
- 3-D Matrix, Ltd. is a Tokyo-based medical technology company specializing in the development, manufacture, and commercialization of innovative medical devices based on proprietary self-assembling peptide technology. The company's core products include hemostatic agents such as PuraStat, PuraShield, and PuraBond, designed for surgical bleeding control across multiple procedural fields including gastrointestinal endoscopy, ear-nose-throat (ENT) surgery, and urology. These peptide-based medical devices promote tissue regeneration and wound healing, targeting applications such as radiation proctitis, inflammatory bowel disease, cosmetic surgery, and cardiovascular treatments. 3-D Matrix operates globally with commercial and research presence in Japan, the United States, Europe, and Australia. Founded in 2007 through the acquisition of the U.S. 3-D Matrix by Japanese interests, the company expanded internationally by obtaining regulatory approvals and launching products across key markets including the U.S. FDA clearance of PuraStat-GI and CE marking for PuraBond in Europe. In the last two years, 3-D Matrix has made significant advancements such as launching PuraShield in Spain for ENT surgical use, and advancing regenerative medicine collaborations, including a recent breakthrough joint research with Harvard University published in the journal Science, which highlights the efficacy of its RADA16 peptide technology in vascularized tissue regeneration. The company secured substantial funding through a ¥1.1 billion convertible bond issuance in mid-2025 to support continued R&D and global expansion. This funding round included participation from key investors such as CVI Investments, Inc. 3-D Matrix targets healthcare professionals and hospitals across a variety of medical segments, focusing on minimally invasive surgery and regenerative medicine markets. Its strategic initiatives center on leveraging its peptide platform to expand indications and enhance patient outcomes worldwide. The company maintains a robust pipeline supported through ongoing research partnerships with leading academic institutions globally, enabling continuous innovation in its medical device offerings. It remains a prominent player in the biotech-medical device industry, positioning itself for growth through product diversification and international market penetration.